ERBB2 and neoplasm: Notably, we have found that patients who show a high degree of HER2 expression on tumor-infiltrated immune cells (by HER2 trogocytosis) demonstrate a significantly greater probability of achieving a pathological complete response (pCR) with trastuzumab-based PST.